Cardiol Therapeutics (TSE:CRDL) Shares Up 2.1% - Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report) shot up 2.1% during trading on Thursday . The stock traded as high as C$1.97 and last traded at C$1.95. 48,665 shares traded hands during mid-day trading, a decline of 35% from the average session volume of 75,373 shares. The stock had previously closed at C$1.91.

Cardiol Therapeutics Trading Up 1.5%

The firm's 50-day simple moving average is C$1.56 and its 200 day simple moving average is C$1.72. The stock has a market cap of C$164.30 million, a P/E ratio of -3.89 and a beta of 0.70. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.